Healthcare, Pharma & Life Sciences
We identify the right patients for the right care. And we ship work that does not get shot down by compliance.
Dilogic is the Strategic Principal for healthcare delivery, pharma commercial, and biotech commercial-stage. Senior partner-led. In-house pharma compliance review. Native to MENA + EU corridors.
The patient identification problem
Five places a patient journey leaks. The leak is rarely where the dashboard says it is.
Healthcare CMOs and growth leads are running CRM dashboards that report leakage at the symptom — referral conversion, no-shows, second-opinion drop. The actual leak is upstream: a clinic's primary care intake never identified the patient as eligible for the specialist program in the first place.
Pharma marketing teams ship campaigns that the client compliance officer rewrites or rejects. The team budgets in days for compliance review; the reality is weeks of rework. The strategic insight that survived discovery does not survive the legal pass.
Dilogic identifies the right patients for the right care AND pre-clears the work in-house before it leaves the building. Compliance is at the strategy table, not as a downstream filter.
Three commitments — sector-aware
What we sign up to inside healthcare and life sciences engagements.
01
We own the bigger picture.
We do not deliver a strategy and leave. We hold the operating thesis across the engagement. The map you have at the end is the map we wrote together — updated by the work, not by a refresh deck.
02
We direct the people who deliver.
Agencies, vendors, internal teams, contractors. Whoever is in the room executing, we direct against the strategy. That includes naming the work, sequencing it, holding it accountable, and replacing what is not working. Direction is not a workshop. It is daily.
03
We are accountable to the outcome.
Engagements are scoped to outcomes, not deliverables. We stay in the room until the outcome lands. If it does not, we say why. Reporting is what happened against what we said would happen — not what is convenient to present.
Why Dilogic for healthcare
Where we sit, and where the alternatives stop.
Global management consultancies' healthcare practices
Macro healthcare strategy, system transformation, regulatory advisory
Channel-thin. Junior-staffed. Slide-deliverable. No in-house pharma compliance.
Channel-deep. Senior-led. Outcome-accountable. In-house pharma compliance review.
Healthcare and pharma agency strategy practices
Brand strategy, communications, HCP engagement bundled with execution
Strategy is a wedge. Compliance is external — work routinely gets shot down by client compliance officer.
Independent of execution. Compliance pre-clearing happens in-house — output reaches the client already aligned to regulatory frame.
Global management consultancies' healthcare practices
What they offer
Macro healthcare strategy, system transformation, regulatory advisory
What they get wrong
Channel-thin. Junior-staffed. Slide-deliverable. No in-house pharma compliance.
What Dilogic does
Channel-deep. Senior-led. Outcome-accountable. In-house pharma compliance review.
Healthcare and pharma agency strategy practices
What they offer
Brand strategy, communications, HCP engagement bundled with execution
What they get wrong
Strategy is a wedge. Compliance is external — work routinely gets shot down by client compliance officer.
What Dilogic does
Independent of execution. Compliance pre-clearing happens in-house — output reaches the client already aligned to regulatory frame.
Healthcare cases
Recent engagements in healthcare and life sciences.
See all healthcare cases →Healthcare insights
What the practice is writing on healthcare and pharma.
See all healthcare insights →FAQ
No. Our concentration is commercial. Healthcare delivery (hospital and clinic groups), pharma commercial (launches, GTM, brand, HCP engagement, exhibitions, patient identification), and biotech commercial-stage. Clinical trial design, biotech molecule strategy, and medtech device engineering are outside our practice.
Engagements that touch pharma, regulated medical claims, or HCP communications run through a compliance review inside Dilogic before output reaches the client's compliance officer. The output we hand over is already aligned to the regulatory frame. The result is fewer rework cycles and faster shipping.
Yes. Biotech is a key focus. Engagements run case-by-case. The firm's pharma muscle and in-house compliance moat translate directly to the commercial-stage challenges biotechs face when their first products approach launch.
Talk to the healthcare practice partner.
Engagements in healthcare begin with a partner-led conversation. Routed to health@dilogicgroup.com.